Cancer Medicine published a research review in June 2025, authored by Dr. Ayesha Shafi, Dr. Gregory Chesnut and George Washington University School of Medicine and Health Sciences medical student Charles Cobbs IV (from the Shafi Lab). The review delves into the pressing issue of racial disparities in prostate cancer outcomes. African American men face higher rates of diagnosis and mortality compared to other racial groups, a disparity driven by complex and intersecting factors.
More on this story on our CPDR News page!
Dr. Arwa Fallatah, Postdoctoral Fellow in the Shafi Lab, was recently awarded a prestigious Prostate Cancer Foundation (PCF) Young Investigator Award. Her project focuses on the role of a circadian rhythm protein, cryptochrome 1 (CRY1), in driving prostate cancer. Circadian rhythm—the body’s “internal clock” that responds to light and dark cycles—helps maintain balance in many biological processes.
Dr. Fallatah and Orly Richter Post-Baccalaureate Researcher, recently presented their work at the American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Baltimore, MD, September 18 - 21, 2025, where Orly won second place in the poster competition. Her poster, titled “Spatial transcriptomic analyses of patient-derived explants identifies biomarkers of aggressive disease,” focused on mapping gene activity within prostate tumors.
For additional details and news, see our CPDR News and Shafi Lab pages!
The CPDR 2nd Annual Scientific Retreat took place on Thursday, April 17 at HJF HQ in Bethesda, and we hosted 150 participants both in-person and virtually. The event included ten distinguished speakers, national leaders in prostate cancer research, and four young scientists from Johns Hopkins University and CPDR. The highlight was the Keynote Address presented by Dr. Isla Garraway, from the University of California Los Angeles David Geffen School of Medicine and the VA Healthcare System, entitled: The VA Multi-OMICS Analysis Platform for Prostate Cancer (VA-MAPP) - Activating a Learning Healthcare System Model to Improve Outcomes for Veterans. The day's agenda featured four insightful sessions covering critical research areas: Genomics of Prostate Cancer, Tumor Immune Microenvironment, Next Generations Cancer Therapeutics, and Advance Molecular Biology of Lethal Prostate Cancer. The 2025 retreat concluded with an impactful presentation from Dr. Artie Shelton, veteran and prostate cancer survivor, and an engaging poster session and award ceremony.
Go to our 2025 Scientific Retreat page for more photos and event details
500+ scientific articles have been published in the past 32 years
Over 268K biospecimen units collected from 9K+ patients
32K military patients with prostate cancer data, integrated with 5 DoD and 1 civilian medical centers in Multicenter National Database Study
Developed and validated emerging diagnostic, prognostic, and therapeutic approaches through a long term (since 1993) bio-molecular specimen bank (230,000 units from 7000+ patients), e.g., ERG oncoprotein-based stratification of prostate cancer (PMID: 22331093) and Oncotype DX Prostate Cancer test (PMID: 25465337, PMID: 26723180).
Walter Reed National Military Medical Center
Building 19, 3rd Floor
4954 North Palmer Rd. Bethesda, MD 20889-5600
Phone: (301) 319-2900